Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases

Overview

Journal Kidney360

Specialty Nephrology

Date 2023 Jul 18

PMID 37461134

Authors

Gregory A Nichols

Efrat L Amitay

Satabdi Chatterjee

Dominik Steubl

Affiliations

Soon will be listed here.

Citing Articles

Cost Offset of Dapagliflozin in the US Medicare Population with Cardio-Kidney Metabolic Syndrome.

Chang R, Miller R, Kwon K, Huang J Adv Ther. 2024; 41(8):3247-3263.

PMID: 38958842 PMC: 11263419. DOI: 10.1007/s12325-024-02919-5.

References

Zeger S, Liang K . Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42(1):121-30. View

Nichols G, Bell T, Pedula K, OKeeffe-Rosetti M . Medical care costs among patients with established cardiovascular disease. Am J Manag Care. 2010; 16(3):e86-e93. View

Liao L, Jollis J, Anstrom K, Whellan D, Kitzman D, Aurigemma G . Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med. 2006; 166(1):112-8. DOI: 10.1001/archinte.166.1.112. View

Gansevoort R, Correa-Rotter R, Hemmelgarn B, Jafar T, Lambers Heerspink H, Mann J . Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382(9889):339-52. DOI: 10.1016/S0140-6736(13)60595-4. View

Gandra S, Lawrence L, Parasuraman B, Darin R, Sherman J, Wall J . Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. J Manag Care Pharm. 2006; 12(7):546-54. PMC: 10437776. DOI: 10.18553/jmcp.2006.12.7.546. View

Nichols G, Glauber H, Brown J . Type 2 diabetes: incremental medical care costs during the 8 years preceding diagnosis. Diabetes Care. 2000; 23(11):1654-9. DOI: 10.2337/diacare.23.11.1654. View

Whaley-Connell A, Sowers J . Basic science: Pathophysiology: the cardiorenal metabolic syndrome. J Am Soc Hypertens. 2014; 8(8):604-6. PMC: 4170524. DOI: 10.1016/j.jash.2014.07.003. View

Nichols G, Ustyugova A, Deruaz-Luyet A, OKeeffe-Rosetti M, Brodovicz K . Health Care Costs by Type of Expenditure across eGFR Stages among Patients with and without Diabetes, Cardiovascular Disease, and Heart Failure. J Am Soc Nephrol. 2020; 31(7):1594-1601. PMC: 7350988. DOI: 10.1681/ASN.2019121308. View

Sukumaran L, McCarthy N, Li R, Weintraub E, Jacobsen S, Hambidge S . Demographic characteristics of members of the Vaccine Safety Datalink (VSD): A comparison with the United States population. Vaccine. 2015; 33(36):4446-50. PMC: 4547875. DOI: 10.1016/j.vaccine.2015.07.037. View

10.

Virani S, Alonso A, Aparicio H, Benjamin E, Bittencourt M, Callaway C . Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021; 143(8):e254-e743. DOI: 10.1161/CIR.0000000000000950. View

11.

Honeycutt A, Segel J, Zhuo X, Hoerger T, Imai K, Williams D . Medical costs of CKD in the Medicare population. J Am Soc Nephrol. 2013; 24(9):1478-83. PMC: 3752941. DOI: 10.1681/ASN.2012040392. View

12.

Nelson R, Ma J, Crook J, Knippenberg K, Nyman H, Paul D . Health Care Costs in a Cohort of HIV-Infected U.S. Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine. J Manag Care Spec Pharm. 2018; 24(10):1052-1066. PMC: 10397780. DOI: 10.18553/jmcp.2018.24.10.1052. View

13.

Shrestha S, Zhang P, Hora I, Gregg E . Trajectory of Excess Medical Expenditures 10 Years Before and After Diabetes Diagnosis Among U.S. Adults Aged 25-64 Years, 2001-2013. Diabetes Care. 2018; 42(1):62-68. PMC: 6393199. DOI: 10.2337/dc17-2683. View

14.

Kwok C, Abramov D, Parwani P, Ghosh R, Kittleson M, Ahmad F . Cost of inpatient heart failure care and 30-day readmissions in the United States. Int J Cardiol. 2020; 329:115-122. DOI: 10.1016/j.ijcard.2020.12.020. View

15.

Nichols G, Reynolds K, Kimes T, Rosales A, Chan W . Comparison of Risk of Re-hospitalization, All-Cause Mortality, and Medical Care Resource Utilization in Patients With Heart Failure and Preserved Versus Reduced Ejection Fraction. Am J Cardiol. 2015; 116(7):1088-92. DOI: 10.1016/j.amjcard.2015.07.018. View

16.

Mahoney E, Wang K, Cohen D, Hirsch A, Alberts M, Eagle K . One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2009; 1(1):38-45. DOI: 10.1161/CIRCOUTCOMES.108.775247. View

17.

Menzin J, Wygant G, Hauch O, Jackel J, Friedman M . One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin. 2008; 24(2):461-8. DOI: 10.1185/030079908x261096. View

18.

Alicic R, Rooney M, Tuttle K . Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017; 12(12):2032-2045. PMC: 5718284. DOI: 10.2215/CJN.11491116. View

19.

Moran J, Solomon P, Peisach A, Martin J . New models for old questions: generalized linear models for cost prediction. J Eval Clin Pract. 2007; 13(3):381-9. DOI: 10.1111/j.1365-2753.2006.00711.x. View

20.

Nichols G, Brown J . The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care. 2002; 25(3):482-6. DOI: 10.2337/diacare.25.3.482. View